MGNX
Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.
MacroGenics, Inc. (MGNX) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Profitability (D+). The rating has held at C+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | B (3.2) | D+ (1.8) | C (2.4) | C+ (2.6) | C+ (2.6) |
| 2026-11-06 | B- (3.0) | B (3.2) | D+ (1.8) | B- (3.0) | C+ (2.7) | C+ (2.7) |
| 2026-10-30 | B- (3.0) | B (3.2) | C- (1.9) | B- (3.0) | C+ (2.7) | C+ (2.8) |
| 2026-10-23 | B- (3.0) | B (3.2) | C- (1.9) | B- (3.1) | C+ (2.6) | C+ (2.8) |
| 2026-10-16 | B- (3.0) | B (3.2) | C- (1.9) | C+ (2.8) | C+ (2.6) | C+ (2.7) |